Table 1 Demographic features, types of idiopathic inflammatory myopathies, autoantibody distribution and therapy of 38 patients immediately before rituximab application (Baseline)
From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Parameters | N = 38 |
|---|---|
Current age (years) | 42.6 ± 10.9 |
Female gender | 32 (84.2) |
White ethnicity | 26 (68.4) |
Disease duration (years) | 3.0 (2.0–6.5) |
Duration time: diagnosis - symptom onset (months) | 4.5 (3.9–9.0) |
Idiopathic inflammatory myopathies | |
Dermatomyositis | 15 (39.5) |
Polymyositis | 10 (26.3) |
Antisynthetase syndrome | 13 (34.2) |
Autoantibodies | |
Antinuclear factor | 31 (81.6) |
Anti-Ro-52 | 16 (42.1) |
Anti-Jo-1 | 13 (34.2) |
Anti-Mi-2 | 4 (10.5) |
Anti-OJ | 0 |
Anti-EJ | 0 |
Anti-PL-7 | 0 |
Anti-PL-12 | 0 |
Prednisone dose (mg/day) | 18.8 (10.0–36.3) |
Methylprednisolone + intravenous human immunoglobulin pulse therapy | 23 (60.5) |